Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | December 19, 2025 | December 23, 2025 |
| Annexon, Inc.ANNX · Entity 5011 | Director | June 11, 2026 | June 15, 2026 |
| Calithera Biosciences, Inc.CALA · Entity 113073 | SR. VP & CFO | November 29, 2016 | December 01, 2016 |
| Protagonist Therapeutics, IncPTGX · Entity 3552 | Director | June 23, 2026 | June 25, 2026 |
| Turnstone Biologics Corp.TSBX · Entity 76646 | Director | June 03, 2024 | July 02, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date December 19, 2025 · Filed December 23, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,563 |
Last balance in matching sequence
After 2025-12-19 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-12-19 · Sale · Disposed 2,416 · Balance 62,514 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 2 · 2025-12-19 · Sale · Disposed 5,451 · Balance 57,063 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. Row 3 · 2025-12-19 · Sale · Disposed 500 · Balance 56,563 F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
F2: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $66.52 to $67.29, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person, a portion of which are still subject to certain vesting conditions.
F4: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $67.58 to $68.48, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $68.51 to $68.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
Annexon, Inc.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2036-06-11 | Direct | 65,000 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 65,000 · Balance 65,000 F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 11, 2026 or (ii) the next Annual Meeting following June 11, 2026, subject to Reporting Person's continuous service as a director until such vesting date.
Calithera Biosciences, Inc.
Report date November 29, 2016 · Filed December 01, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.35 · Expires 2026-11-28 | Direct | 75,000 |
Reported balance
After 2016-11-29 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2016-11-29 · Grant · Acquired 75,000 · Balance 75,000 F1: One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company.
Protagonist Therapeutics, Inc
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 7,825 |
Ending reported balance
After 2026-06-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-23 · Exercise / conversion · Acquired 9,000 · Balance 16,825 F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026. Row 2 · 2026-06-23 · Sale · Disposed 9,000 · Balance 7,825 F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.54 · Expires 2030-05-27 | Direct | 0 |
Reported balance
After 2026-06-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-23 · Exercise / conversion · Disposed 9,000 · Balance 0 F3: These stock options are fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions set forth on this Form 4 were effected pursuant to a 10b5-1 plan adopted by the reporting person on February 27, 2026.
F2: The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $117.00 to $119.07. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
F3: These stock options are fully vested.
Turnstone Biologics Corp.
Report date June 03, 2024 · Filed July 02, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.69 · Expires 2034-06-02 | Direct | 12,770 |
Reported balance
After 2024-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-03 · Grant · Acquired 12,770 · Balance 12,770 F1: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest on the earlier of June 3, 2025 or the date of the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 11, 2024 Filed Jan 16, 2024 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,634 | $37.81 | $99,591.54 |
DisclosureSEC source: 0001628280-24-001424 · wk-form4_1705446389.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,170 F1 · kind: Shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported on Column 4 is the weighted average price. These shares were sold in multiple transactions at prices ranging from $37.50 to $38.25, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · acquired: Partial disposition of RSUs to satisfy tax withholding obligations. F4 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| January 02, 2024 Filed Jan 5, 2024 01:17 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 25,700 | $0.00 Strike: $23.42 | $0.00 |
DisclosureSEC source: 0001104659-24-001497 · tm241954-9_4seq1.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,700 Underlying: Common Stock · 25,700 shares Expires 2034-01-02 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following January 2, 2024, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| December 15, 2023 Filed Dec 19, 2023 20:41 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 14,987 | $25.41 | $380,819.67 |
DisclosureSEC source: 0001628280-23-041960 · wk-form4_1703018485.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,804 F1 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary date. Read SEC document |
| June 08, 2023 Filed Jun 12, 2023 20:45 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001610717-23-000141 · form4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2033-06-08 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 8, 2023 or (ii) the next Annual Meeting following June 8, 2023, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| January 16, 2023 Filed Jan 19, 2023 01:07 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $12.17 | $0.00 |
DisclosureSEC source: 0001104659-23-004735 · tm233829-4_4seq1.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2033-01-15 F1 · derivative.exercise_date: The stock option vests in 12 equal monthly installments following the date of grant. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock · Derivative | 4,593 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-23-003073 · doc4.xml · derivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 4,593 shares Expires 2033-01-10 F3 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003073 · doc4.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,817 F2 · shares: Represents shares underlying restricted stock units, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 09, 2023 Filed Jan 12, 2023 01:23 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,200 | $30.00 | $96,000.00 |
DisclosureSEC source: 0001209191-23-003073 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,950 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 20:42 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 24,000 | $0.00 Strike: $3.84 | $0.00 |
DisclosureSEC source: 0001567619-22-012780 · doc1.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2032-06-09 F1 · derivative.exercise_date: The underlying shares subject to the option vest and become exercisable as to 100% of the total number of shares subject to the option on the earlier of (i) the first anniversary of June 9, 2022 or (ii) the next Annual Meeting following June 9, 2022, subject to Reporting Person's continuous service as a director until such vesting date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:02 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $8.31 | $0.00 |
DisclosureSEC source: 0001104659-22-065869 · tm2214526-8_4seq1.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: The stock option vests in full on the earlier of (i) May 26, 2023 or (ii) the date of the Issuer's 2023 Annual Meeting of Stockholders, subject to the Reporting Person's continued service with the Issuer through such date. Read SEC document |
| May 03, 2022 Filed May 5, 2022 00:41 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001104659-22-056000 · tm2214526-1_4seq1.xml · derivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 12,000 shares Expires 2027-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to this option are vested in full. Read SEC document |
| May 03, 2022 Filed May 5, 2022 00:41 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | Exercise / conversionCommon Stock | 12,000 | $8.59 | $103,080.00 |
DisclosureSEC source: 0001104659-22-056000 · tm2214526-1_4seq1.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 07, 2022 Filed Jan 8, 2022 01:14 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002597 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,150 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:35 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 272 | $66.25 | $18,020.00 |
DisclosureSEC source: 0001209191-22-001331 · doc4.xml · nonDerivative · entry 3 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,750 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:35 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,128 | $65.01 | $138,341.28 |
DisclosureSEC source: 0001209191-22-001331 · doc4.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,022 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.73 to $65.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:35 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,100 | $64.23 | $134,883.00 |
DisclosureSEC source: 0001209191-22-001331 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,150 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. The shares were sold pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to $64.71, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| August 12, 2021 Filed Aug 16, 2021 21:18 UTC | Annexon, Inc. ANNX · Entity 5011 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $19.73 | $0.00 |
DisclosureSEC source: 0001567619-21-015937 · doc1.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2031-08-12 F1 · derivative.exercise_date: 1/36th of the shares subject to the option vest on each monthly anniversary measured from August 12, 2021 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date. Read SEC document |
| May 27, 2021 Filed May 28, 2021 23:02 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $35.23 | $0.00 |
DisclosureSEC source: 0001209191-21-036670 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-05-26 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 27, 2022, or (ii) the date of the 2022 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| January 04, 2021 Filed Jan 5, 2021 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 3,750 | $76.08 | $285,300.00 |
DisclosureSEC source: 0001209191-21-001481 · doc4.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,250 F2 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $75.86 to $76.32, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:01 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001481 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 23:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,800 | $73.10 | $131,580.00 |
DisclosureSEC source: 0001209191-20-063035 · doc4.xml · nonDerivative · entry 2 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Read SEC document |
| December 10, 2020 Filed Dec 11, 2020 23:16 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,200 | $68.50 | $82,200.00 |
DisclosureSEC source: 0001209191-20-063035 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,800 Read SEC document |
| May 28, 2020 Filed May 29, 2020 22:19 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $16.54 | $0.00 |
DisclosureSEC source: 0001209191-20-033031 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-05-27 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) May 28, 2021, or (ii) the date of the 2021 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| May 11, 2020 Filed May 13, 2020 22:45 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 26,000 | $36.54 | $950,040.00 |
DisclosureSEC source: 0001209191-20-028975 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.25 to $37.07, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 23:06 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001359 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 22:33 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $11.80 | $0.00 |
DisclosureSEC source: 0001209191-19-036214 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2029-06-06 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier of (i) June 7, 2020, or (ii) the date of the 2020 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| January 11, 2019 Filed Jan 11, 2019 23:15 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 8,500 | $14.77 | $125,545.00 |
DisclosureSEC source: 0001209191-19-003464 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 F1 · kind: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| January 01, 2019 Filed Jan 4, 2019 01:18 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 30,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-001551 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| May 29, 2018 Filed Jun 12, 2018 22:52 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $6.98 | $0.00 |
DisclosureSEC source: 0001209191-18-037317 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-05-28 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier on (i) May 29, 2019, or (ii) the date of the 2019 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| January 01, 2018 Filed Jan 4, 2018 00:46 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 25,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-001549 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| May 25, 2017 Filed May 26, 2017 21:37 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $8.59 | $0.00 |
DisclosureSEC source: 0001209191-17-035969 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-05-25 F1 · derivative.exercise_date: The shares subject to this option shall vest at the earlier on (i) May 25, 2018, or (ii) the date of the 2018 Annual Meeting of stockholders of the Issuer, subject to the non-employee director's continuous service with the Issuer through such dates. The shares subject to this option will vest in full upon completion of a Change in Control (as defined in the Issuer's 2016 Equity Incentive Plan). Read SEC document |
| November 29, 2016 Filed Dec 1, 2016 16:05 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $3.35 | $0.00 |
DisclosureSEC source: 0000899243-16-034662 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · SR. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2026-11-28 F1 · derivative.exercise_date: One-fourth (1/4th) of the Option vests one year after November 29, 2016; the balance of the Option vests in a series of thirty-six (36) successive equal monthly installments thereafter. The Option shall be subject to accelerated vesting as set forth in the optionee's employment agreement with the Company. Read SEC document |
| September 29, 2016 Filed Oct 3, 2016 21:41 UTC | Calithera Biosciences, Inc. CALA · Entity 113073 | OtherCommon Stock | 17,485 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-16-030612 · doc4.xml · nonDerivative · entry 1 Waddill William D. · CIK 0001553338 · SR. VP & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,485 F1 · shares: Represents shares transferred to the reporting person's ex-spouse pursuant to a divorce decree. The securities owned by the ex-spouse are not beneficially owned by the reporting person. Read SEC document |
| September 13, 2016 Filed Sep 15, 2016 20:27 UTC | Protagonist Therapeutics, Inc PTGX · Entity 3552 | GrantStock Option (right to buy) · Derivative | 24,000 | $0.00 Strike: $12.88 | $0.00 |
DisclosureSEC source: 0001209191-16-141595 · doc4.xml · derivative · entry 1 Waddill William D. · CIK 0001553338 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,000 Underlying: Common Stock · 24,000 shares Expires 2026-09-13 F1 · derivative.exercise_date: The shares subject to the option shall vest in equal monthly installments over a three-year period from the vesting commencement date of August 10, 2016. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.